CN1554440A - 治疗妇科疾病的药物组合物 - Google Patents
治疗妇科疾病的药物组合物 Download PDFInfo
- Publication number
- CN1554440A CN1554440A CNA2004100341638A CN200410034163A CN1554440A CN 1554440 A CN1554440 A CN 1554440A CN A2004100341638 A CNA2004100341638 A CN A2004100341638A CN 200410034163 A CN200410034163 A CN 200410034163A CN 1554440 A CN1554440 A CN 1554440A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- medicine
- blood
- group
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 63
- 239000008194 pharmaceutical composition Substances 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 26
- 239000002994 raw material Substances 0.000 claims description 5
- 239000008280 blood Substances 0.000 abstract description 44
- 210000004369 blood Anatomy 0.000 abstract description 44
- 230000006870 function Effects 0.000 abstract description 15
- 230000008961 swelling Effects 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 206010011732 Cyst Diseases 0.000 abstract description 5
- 208000031513 cyst Diseases 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 241001404789 Smilax glabra Species 0.000 abstract description 2
- 210000001672 ovary Anatomy 0.000 abstract description 2
- 206010006272 Breast mass Diseases 0.000 abstract 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 240000007890 Leonurus cardiaca Species 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 244000179291 Mahonia aquifolium Species 0.000 abstract 1
- 241000913745 Spatholobus Species 0.000 abstract 1
- 241001078983 Tetradium ruticarpum Species 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 230000036407 pain Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 210000000481 breast Anatomy 0.000 description 20
- 206010046798 Uterine leiomyoma Diseases 0.000 description 18
- 206010006298 Breast pain Diseases 0.000 description 15
- 208000006662 Mastodynia Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 210000001015 abdomen Anatomy 0.000 description 11
- 239000002131 composite material Substances 0.000 description 11
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 208000025661 ovarian cyst Diseases 0.000 description 10
- 238000011084 recovery Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 208000029312 Muscular tumor Diseases 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 230000005906 menstruation Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 210000004291 uterus Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 210000005075 mammary gland Anatomy 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- 239000009306 yunnan baiyao Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 230000004856 capillary permeability Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 238000003748 differential diagnosis Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000003821 menstrual periods Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Chemical compound COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008956 guizhi-fuling Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 238000012109 statistical procedure Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001407408 Berberis fortunei Species 0.000 description 3
- -1 GDT Chemical compound 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002607 hemopoietic effect Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 238000009592 kidney function test Methods 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000009666 routine test Methods 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 2
- 241000736253 Berberis bealei Species 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 2
- VELYAQRXBJLJAK-MJSCJBMMSA-N Leonuridine Chemical compound C12C(C)(O)CC(O)C2C=COC1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VELYAQRXBJLJAK-MJSCJBMMSA-N 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- JYAPBWCAZXNDAR-UHFFFAOYSA-N Oxyacanthine Natural products COc1cc2CCN(C)C3Cc4ccc(Oc5cccc(CC6N(C)CCc7cc(OC)c(OC)c(Oc(c1)c23)c67)c5)c(O)c4 JYAPBWCAZXNDAR-UHFFFAOYSA-N 0.000 description 2
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000297 inotrophic effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- HGNHIFJNOKGSKI-WDYNHAJCSA-N oxyacanthine Chemical compound C([C@H]1N(C)CCC=2C=C(C(OC=3C(OC)=C(OC)C=C4CCN(C)[C@H](C=34)CC3=CC=C(C=C3)O3)=CC=21)OC)C1=CC=C(O)C3=C1 HGNHIFJNOKGSKI-WDYNHAJCSA-N 0.000 description 2
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- OTEKOJQFKOIXMU-UHFFFAOYSA-N 1,4-bis(trichloromethyl)benzene Chemical compound ClC(Cl)(Cl)C1=CC=C(C(Cl)(Cl)Cl)C=C1 OTEKOJQFKOIXMU-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- XUDNWQSXPROHLK-OACYRQNASA-N 2-phenyl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC=CC=2)OC2=CC=CC=C2C1=O XUDNWQSXPROHLK-OACYRQNASA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 241001415145 Acnistus arborescens Species 0.000 description 1
- 208000007743 Acute Abdomen Diseases 0.000 description 1
- DFOCUWZXJBAUSQ-URLMMPGGSA-N Berbamine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(OC=3C(OC)=C(OC)C=C4CCN(C)[C@@H](C=34)CC=3C=C(C(=CC=3)O)O3)=CC=21)OC)C1=CC=C3C=C1 DFOCUWZXJBAUSQ-URLMMPGGSA-N 0.000 description 1
- DFOCUWZXJBAUSQ-UHFFFAOYSA-N Berbamine Natural products O1C(C(=CC=2)O)=CC=2CC(C=23)N(C)CCC3=CC(OC)=C(OC)C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 DFOCUWZXJBAUSQ-UHFFFAOYSA-N 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- 241001083847 Berberis Species 0.000 description 1
- 206010057687 Bloody discharge Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241001111309 Carronia Species 0.000 description 1
- 241000283026 Cervus elaphus Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 208000009774 Follicular Cyst Diseases 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 240000003271 Leonurus japonicus Species 0.000 description 1
- 241001347978 Major minor Species 0.000 description 1
- 241000440580 Mammaria Species 0.000 description 1
- PWUCIPXNTHJNJC-UHFFFAOYSA-N Matairesinoside Natural products COc1cc(CC2C(Cc3ccc(OC4OC(CO)C(O)C(O)C4O)c(OC)c3)CCC2=O)ccc1O PWUCIPXNTHJNJC-UHFFFAOYSA-N 0.000 description 1
- AAGCATAPYOEULE-UHFFFAOYSA-N Matairesinoside aglycone Natural products C1=C(O)C(OC)=CC(CC2C(C(=O)OC2)CC=2C=C(OC)C(OC3C(C(O)C(O)C(CO)O3)O)=CC=2)=C1 AAGCATAPYOEULE-UHFFFAOYSA-N 0.000 description 1
- 241001079002 Melicope pteleifolia Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 241000700145 Petromus typicus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241001302750 Psychotria rubra Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001423398 Ruscus hypoglossum Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000800405 Spatholobus suberectus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940046358 diethylstilbestrol 0.1 mg Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000022168 hypermenorrhea Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AAGCATAPYOEULE-LHHMAMHXSA-N matairesinoside Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)=C1 AAGCATAPYOEULE-LHHMAMHXSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940056692 resinol Drugs 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410034163 CN1219547C (zh) | 2004-04-26 | 2004-04-26 | 治疗妇科疾病的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410034163 CN1219547C (zh) | 2004-04-26 | 2004-04-26 | 治疗妇科疾病的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1554440A true CN1554440A (zh) | 2004-12-15 |
CN1219547C CN1219547C (zh) | 2005-09-21 |
Family
ID=34352239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410034163 Ceased CN1219547C (zh) | 2004-04-26 | 2004-04-26 | 治疗妇科疾病的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1219547C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101897873A (zh) * | 2010-07-30 | 2010-12-01 | 云南良方制药有限公司 | 消结安提取物的制备方法 |
CN105535490A (zh) * | 2016-01-12 | 2016-05-04 | 刘文银 | 一种结合超声介入治疗卵巢囊肿的中药及其制备方法 |
CN106166188A (zh) * | 2016-08-30 | 2016-11-30 | 罗嘉辉 | 一种治疗乳腺增生的中药 |
-
2004
- 2004-04-26 CN CN 200410034163 patent/CN1219547C/zh not_active Ceased
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101897873A (zh) * | 2010-07-30 | 2010-12-01 | 云南良方制药有限公司 | 消结安提取物的制备方法 |
CN101897873B (zh) * | 2010-07-30 | 2011-10-26 | 云南良方制药有限公司 | 活血化瘀、软解散结提取物的制备方法 |
CN105535490A (zh) * | 2016-01-12 | 2016-05-04 | 刘文银 | 一种结合超声介入治疗卵巢囊肿的中药及其制备方法 |
CN106166188A (zh) * | 2016-08-30 | 2016-11-30 | 罗嘉辉 | 一种治疗乳腺增生的中药 |
Also Published As
Publication number | Publication date |
---|---|
CN1219547C (zh) | 2005-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103463539B (zh) | 一种治疗湿疹的药物及其制备方法和用途 | |
CN104162094B (zh) | 一种治疗肥胖型多囊卵巢综合征的中药组合物及其药物制剂 | |
CN101002847A (zh) | 治疗乳腺增生的药物及其制备方法 | |
CN105998297A (zh) | 一种润肠通便的中药组合物及其制备方法 | |
CN110478452A (zh) | 一种治疗痛风的中药组合物及其制备方法 | |
CN1724022A (zh) | 防治子宫异常出血病的中药复方制剂及其生产方法 | |
CN1255154C (zh) | 鹿胎颗粒中药制剂及生产工艺 | |
CN1219547C (zh) | 治疗妇科疾病的药物组合物 | |
CN104383257A (zh) | 一种治疗肝郁阴虚型干眼症的中药制剂 | |
CN104524247B (zh) | 一种治疗偏头痛的药物组合物及其用途 | |
CN1301129C (zh) | 一种治疗风寒湿痹及筋骨萎软的药物 | |
CN103191399A (zh) | 用于治疗支气管哮喘急性发作期的中药组合物 | |
CN101249236B (zh) | 一种治疗癫痫的中西医药结合制剂 | |
CN1284589C (zh) | 一种治疗急性脑血管疾病的药物及其制备方法 | |
CN1709448A (zh) | 一种治疗妇女疾病的藏药药物及其制备方法 | |
CN103816339A (zh) | 一种治疗肝郁痰凝型乳腺增生的中药颗粒剂 | |
CN109432364A (zh) | 用于产后恢复的参芪益母中药组合物及其制备方法与应用 | |
CN1209162C (zh) | 治疗痤疮、黄褐斑的药物组合物 | |
CN102813888A (zh) | 一种治疗癫痫病的中药组合物 | |
CN109381662A (zh) | 治疗前列腺癌的中药组合物及其制备方法和用途 | |
CN1723939A (zh) | 排卵助孕丸 | |
CN100350953C (zh) | 一种治疗病毒感染性高热病的药物组合物及其制备方法 | |
CN104906194A (zh) | 一种治疗哮喘的药物贴膏及制备工艺与检测分析方法 | |
CN104491556B (zh) | 一种治疗肝郁气滞型前列腺增生的中药组合物 | |
CN104352561A (zh) | 一种含怀牛膝的降血压用中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Chen Yulong Document name: Notice of oral request for invalidation |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Benshan Pharmaceutical Co., Ltd., Yunnan Document name: Notice of oral request for invalidation |
|
C56 | Change in the name or address of the patentee |
Owner name: YUNNAN LIANGFANG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: BENSHAN PHARMACEUTICAL CO., LTD., YUNAN PROV. |
|
CP03 | Change of name, title or address |
Address after: Yunnan city in Kunming Province Economic and Technological Development Zone by the State Road No. 3 Patentee after: Yunnan Liangfang Pharmaceutical Co., Ltd. Address before: Yunnan province Kunming city closed road No. 169, Hongxing tower A 9 floor Patentee before: Benshan Pharmaceutical Co., Ltd., Yunnan |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Zhang Yi Document name: Notice of termination |
|
ASS | Succession or assignment of patent right |
Owner name: CHEN HONGYING Free format text: FORMER OWNER: YUNNAN LIANGFANG PHARMACEUTICAL CO., LTD. Effective date: 20110906 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20110906 Address after: 650217 Kunming science and Technology Innovation Park, No. 3, opening Road, national economic and Technological Development Zone, Yunnan, Kunming province A42 Patentee after: Chen Hongying Address before: 650217 Yunnan city of Kunming Province Economic and Technological Development Zone by the State Road No. 3 Patentee before: Yunnan Liangfang Pharmaceutical Co., Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20041215 Assignee: Yunnan Liangfang Pharmaceutical Co., Ltd. Assignor: Chen Hongying Contract record no.: 2012530000081 Denomination of invention: Medicinal composition for treating synecopathy Granted publication date: 20050921 License type: Exclusive License Record date: 20120919 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C35 | Partial or whole invalidation of patent or utility model | ||
IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20111209 Decision number of declaring invalidation: 17631 Granted publication date: 20050921 |
|
C35 | Partial or whole invalidation of patent or utility model | ||
IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20111209 Decision number of declaring invalidation: 17631 Granted publication date: 20050921 |
|
C35 | Partial or whole invalidation of patent or utility model | ||
IP01 | Partial invalidation of patent right |
Decision date of declaring invalidation: 20111209 Decision number of declaring invalidation: 17631 Granted publication date: 20050921 |
|
C35 | Partial or whole invalidation of patent or utility model | ||
IP01 | Partial invalidation of patent right |
Decision date of declaring invalidation: 20111209 Decision number of declaring invalidation: 17631 Granted publication date: 20050921 |
|
C35 | Partial or whole invalidation of patent or utility model | ||
IP01 | Partial invalidation of patent right |
Decision date of declaring invalidation: 20111209 Decision number of declaring invalidation: 17631 Granted publication date: 20050921 |
|
C35 | Partial or whole invalidation of patent or utility model | ||
IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20111209 Decision number of declaring invalidation: 17631 Granted publication date: 20050921 |